Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

2.

The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.

Cowey CL, Fielding JR, Rathmell WK.

Urology. 2010 May;75(5):1108-13.e1. doi: 10.1016/j.urology.2009.06.105. Epub 2009 Nov 20.

PMID:
19931124
3.

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death.

Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD.

Mol Cancer Ther. 2008 Nov;7(11):3546-55. doi: 10.1158/1535-7163.MCT-08-0569.

4.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

5.

Tumor cell metabolism: cancer's Achilles' heel.

Kroemer G, Pouyssegur J.

Cancer Cell. 2008 Jun;13(6):472-82. doi: 10.1016/j.ccr.2008.05.005. Review.

6.

Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C.

Montel-Hagen A, Kinet S, Manel N, Mongellaz C, Prohaska R, Battini JL, Delaunay J, Sitbon M, Taylor N.

Cell. 2008 Mar 21;132(6):1039-48. doi: 10.1016/j.cell.2008.01.042.

7.

Advances in positron emission tomography applications for urologic cancers.

Larson SM, Schöder H.

Curr Opin Urol. 2008 Jan;18(1):65-70. Review.

PMID:
18090493
8.

Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.

Pajor AM, Randolph KM, Kerner SA, Smith CD.

J Pharmacol Exp Ther. 2008 Mar;324(3):985-91. Epub 2007 Dec 6.

9.

GLUT1 deficiency syndrome--2007 update.

Klepper J, Leiendecker B.

Dev Med Child Neurol. 2007 Sep;49(9):707-16. Review.

10.

Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ.

Cancer Res. 2007 Jun 15;67(12):5896-905.

11.

Differential expression of facilitative glucose transporters in normal and tumour kidney tissues.

Suganuma N, Segade F, Matsuzu K, Bowden DW.

BJU Int. 2007 May;99(5):1143-9.

12.

Renal cell carcinoma.

Rathmell WK, Martz CA, Rini BI.

Curr Opin Oncol. 2007 May;19(3):234-40. Review.

PMID:
17414642
13.

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption.

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC.

Cell Metab. 2006 Mar;3(3):187-97.

14.
15.

A mouse model for Glut-1 haploinsufficiency.

Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC.

Hum Mol Genet. 2006 Apr 1;15(7):1169-79. Epub 2006 Feb 23.

PMID:
16497725
16.

Gene signatures of progression and metastasis in renal cell cancer.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA.

Clin Cancer Res. 2005 Aug 15;11(16):5730-9.

17.

Why do cancers have high aerobic glycolysis?

Gatenby RA, Gillies RJ.

Nat Rev Cancer. 2004 Nov;4(11):891-9. Review.

PMID:
15516961
19.

On respiratory impairment in cancer cells.

WARBURG O.

Science. 1956 Aug 10;124(3215):269-70. No abstract available.

PMID:
13351639
20.

On the origin of cancer cells.

WARBURG O.

Science. 1956 Feb 24;123(3191):309-14. No abstract available.

PMID:
13298683

Supplemental Content

Support Center